NCT03369574

Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab

Prospective Observational Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab

• Status: Withdrawn
• Phase: —
• Study type: Observational
• Enrollment: 0 (actual)
• Sponsor: University of Rochester · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this research is to monitor chronic rhinosinusitis (CRS) symptoms in asthma patients who are undergoing treatment with reslizumab. A secondary objective is to explore whether there are sub-populations that appear to benefit or not benefit from reslizumab in terms of their CRS symptoms.

Detailed description

This is a prospective observational study of patients receiving reslizumab to treat their asthma. Some asthma patients receiving reslizumab also have CRS, which might also be improved by this drug. Study measures will be obtained from the medical records of eligible subjects who consent to participate. The study has no specific procedures per se, because all study measures are acquired during the course of standard of care treatment and will be abstracted from those medical records.

Conditions

• Chronic Rhinosinusitis (Diagnosis)
• Asthma
• Nasal Polyps

Interventions

Type	Name	Description
DRUG	Reslizumab	reslizumab administration

Timeline

• Start date: 2017-11-14
• Primary completion: 2018-10-19
• Completion: 2018-10-19
• First posted: 2017-12-12
• Last updated: 2019-11-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study